A Study of Single-Agent AT-101 in Men With Hormone Refractory Prostate Cancer
Status:
Completed
Trial end date:
2007-06-01
Target enrollment:
Participant gender:
Summary
This is an open-label, multicenter Phase I/II study to evaluate the safety and efficacy of
single-agent AT-101 in men with hormone-refractory prostate cancer.